PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Addict Behav. Author manuscript; available in PMC 2010 June 1.
Published in final edited form as:
PMCID: PMC2710302
NIHMSID: NIHMS107507

Nicotine Withdrawal and Craving in Adolescents: Effects of Sex and Hormonal Contraceptive Use

Abstract

While sex differences in the nicotine withdrawal (NW) symptoms and craving (NC) have been extensively described in adult cigarette smokers, few studies have investigated these phenomena in adolescents. We investigated the effect of gender and hormonal contraception (HC) on NW and NC during the first 14 days of cessation in adolescent smokers using data from a randomized, placebo-controlled, double-blind trial of the transdermal nicotine replacement therapy for smoking cessation.

Analyses showed similar levels of NW severity in males and females, regardless of HC use. However, significantly higher NC was observed in females compared to males, (2.22±0.12 vs. 1.65±1.14; p=0.003). Further, females not using HC reported the highest level of NC (2.38±0.16) followed by females using HC (2.08±0.25) and males (1.71±0.16; p=0.007).

The current findings suggest that adolescent females experience similar NW severity to males, but have stronger NC. Further, the use of hormonal contraceptives may impact the severity of craving. Addressing these different symptoms in adolescents may be useful in increasing smoking cessation rates in this special population of smokers.

Keywords: Nicotine withdrawal, sex, adolescence, hormonal contraception, birth control

1. Introduction

While gender differences in nicotine withdrawal (NW) and craving (NC) in adult cigarette smokers have been well studied (Leventhal, Waters, Boyd, Moolchan, Lerman, & Pickworth, 2007; Hogle & Curtin, 2006; Carpenter, Upadhyaya, LaRowe, Saladin, & Brady, 2006), sex differences in adolescent smokers have only recently been explored (Smith, Cavallo, Dahl, Wu, George & Krishnan-Sarin, 2008; Panday, Reddy, Ruiter, Berstrom & de Vries, 2007). Adolescent smokers quickly develop nicotine dependence and most experience NW during smoking cessation (DiFranza, Savageau, Fletcher et al, 2007). Female adolescent smokers may experience more severe NW than males (Panday et al, 2007), although withdrawal symptoms appear to resolve more quickly in females (Smith et al, 2008). As yet, the possible role of female sex hormones in nicotine withdrawal in adolescent smokers, including hormone contraceptives, has not been described. Benowitz and colleagues (2006) reported that women who used combined oral contraceptives or estrogen-only contraceptives had faster nicotine metabolism than those who took no hormones.

The animal literature supports a role of ovarian hormones in addictive drug behavior. There is strong evidence of drug self-administration via alterations in dopamine functioning in reward areas of the brain where estrogen has been suggested to enhance this dopamine reward system (Disshon & Dluzen, 1999; Thompson & Moss, 1994). However, clinical studies are not as clear about the role of ovarian hormones. Some retrospective trials (Perkins, Levine, Marcus et al, 2000; O’Hara, Portser & Anderson, 1989) have shown that women who happen to quit in the luteal phase have greater withdrawal. Yet other studies show no effect of cycle phase with intranasal nicotine (Marks, Pomerleau, & Pomerleau, 1999). Some retrospective analyses suggest that (Franklin, Ehrman, Lynch et al, 2008; Carpenter, Saladin, Leinbach, Larowe, & Upadhyaya, 2008) in women on nicotine replacement therapy (NRT) who quit in the luteal phase experience worse outcomes compared to follicular phase. On the other hand, another randomized trial of women not on NRT quitting in different phases of the menstrual cycle showed that women who quit in the follicular phase had poorer outcomes (Allen, Bade, Center, Finstad & Hatsukami, 2008). Although clinical results are mixed, there is a suggestion that ovarian hormones may play a role in women’s ability to quit.

Given this background, the purpose of the current report was to compare NW and NC in adolescent males, adolescent females not currently using hormonal contraceptives, and adolescent females using hormonal contraceptives (HC). The current report draws on data collected as part of a double-blind, placebo-controlled, randomized study of transdermal NRT in adolescent smokers (Hanson, Allen, Jensen & Hatsukami, 2003). We hypothesized that female adolescents would report more severe NW symptoms than male adolescents. Additionally, we hypothesized that adolescent females using hormonal contraceptives would exhibit more intense withdrawal symptoms compared to adolescent females not using hormonal contraceptives.

2. Methods

2.1 Participants

A complete description of study methods is provided elsewhere (Hanson et al, 2003). This study was reviewed and approved by the Institutional Review Board at the University of Minnesota. Participants under the age of 18 years were required to have parental written informed consent. Eligible participants: (1) were between the ages of 13–19; (2) smoked ≥10 cigarettes/day for at least 6 months; (3) were motivated to quit smoking (indicated by a score greater than or equal to 7, using a scale from 0 [not motivated at all] to 10 [very much motivated]; (4) did not use any other tobacco products more than once per week; and (5) were not currently using any form of nicotine replacement therapy (NRT). Exclusion criteria included: (1) current alcohol abuse or drug abuse problems; (2) severe emotional problems within the past year; (3) use of psychoactive medications (except those used to treat attention-deficit/hyperactivity disorder) within the past six months; and (4) were unable to use the nicotine patch due to medical contraindications.

2.2 Procedures

Over the course of the 12-week study conducted from 1997 to 1999, participants attended a total of 13 visits at their respective school or at the Tobacco Use Research Center (TURC): visit -1 was orientation and a medical screening, visit 0 during week 1, when nicotine or placebo patch was randomly assigned, visits 1–2 during week 2 with visit 1 being the target quit date, visits 3–8 weekly for 6 weeks, and visits 9 and 10 biweekly for the final 4 weeks of treatment. Participants quit smoking the morning of visit 1. Data for this study was limited to the first two weeks post quit date when the greatest severity of withdrawal symptoms would be expected. At each treatment visit, both active patch and placebo groups received 10–15 minutes of individual cognitive behavioral therapy provided by a trained counselor. Expired-air carbon monoxide levels were measured at each visit using the Bedfont Micro Smokerlyzer device to determine abstinence. Participants were declared abstinent at a given time if (a) they attained CO levels ≤5 ppm at clinic visits and (b) they reported no cigarettes smoked on the daily diary. Salivary cotinine levels from participants were collected but only samples from participants in the placebo patch group were examined. This was used with the CO levels to determine false positives and negatives. A salivary cotinine level of ≤15ng/ml was considered abstinent (Hanson et al, 2003).

2.3 Measures

At the baseline visit, demographic and smoking history questionnaires and the Fagerstrom Test of Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker & Fagerstrom, 1991) were completed. Additionally, the participant’s medications and birth control use were documented in the participant’s medical record and verified by the study physician. The Minnesota Nicotine Withdrawal Scale (MNWS), a self-rated measure found to be a sensitive indicator of NW and NC, was the primary dependent variable in this study (Hughes & Hatsukami, 1986; Hughes & Hatsukami, 1998). NW was defined as the total of the 7 seven individual items, excluding craving, while NC was indicted by the separate craving item. Participants completed the MNWS at each clinic visit.

2.4 Data Analytic Methods

Data were analyzed using the Statistical Analysis System 9.1.3. (SAS Institute Inc., 2007). Values of p<0.05 were considered statistically significant, based on two-tailed tests. Male (n=43) and female smokers (n=57) were compared using t-tests and chi-square tests. Analyses focused on first 2 weeks of cessation when the greatest nicotine withdrawal severity was anticipated. The primary analytic strategy was repeated-measures analysis of covariance including as predictors: sex (or sex with females broken out by HC use), time, and their interaction. Covariates included patch condition, age, FTND, having previously quit for 24 hours or more, and average values of the MNWS during the time preceding the analysis period (visit -1 and visit 0). Smoking status was treated as a time varying covariate for days 1, 7, and 14.

3. Results

3.1 Sample Characteristics

Comparison of male and female participants revealed no significant differences on demographic and smoking history variables (Table 1).

Table 1
Participant Demographics

3.2 Sex Differences in Nicotine Withdrawal and Craving

In the first 14 days of treatment, females, on average (± standard error) reported similar levels of total withdrawal as seen in males (7.7±0.60 vs. 6.4±0.66, respectively; F(1,76) = 2.30, p = 0.1333. Analysis of NC revealed a sex effect on craving such that females reported higher craving than males (2.22± 0.12 vs. 1.65±1.14, respectively; F(1,76.7)=9.15, p = 0.0034. NC tended to decline in the time since the quit day, F(2, 73.3) = 9.10, p = 0.0003. See Figure 1.

Figure 1
Craving scores during the first 14-days of treatment by sex and day of cessation. (females = 57, males = 43).

3.3 Hormonal Contraception Effects on Nicotine Withdrawal

Of the 57 female participants, 18 (32%) reported using hormonal contraception, 12 (67%) combined, 6 (33%) progesterone-only. The above analyses were repeated, partitioning sex into male, female without HC, and female with HC. Results showed no effect of hormonal contraceptives on total withdrawal or withdrawal excluding craving. However, there was evidence that hormonal contraceptives affected craving as a single item such that females with HC reported the highest level of craving (2.38±0.16), followed by females without HC (2.11± 0.25) then males (1.71± 0.16; F(2, 75.3) = 5.20, p = 0.0077). Again, NC tended to decline in the time since the quit day, F(2, 76.2) = 7.33, p = 0.0012. See Figure 2.

Figure 2
Craving scores during the first 14-days of treatment by sex and hormonal contraceptive use and day of cessation. (females with HC = 18, females without HC = 39, males = 43).

4. Discussion

At variance with recent reports, adolescent females in our sample reported similar NW to adolescent males (Smith et al, 2008; Panday et al, 2007). However, females reported higher levels of craving than males. Studies have shown that nicotine replacement is not as effective for women compared to men (Hatsukami, Skoog, Allen & Bliss, 1995; Gourlay, Forbes, Marriner, Pethica & McNeil, 1994; Bjornson, Rand, Connett, et al, 1995; Swan, Jack & Ward, 1997; Perkins, 1999) and this may have partially contributed to the observed increased craving seen in the female adolescents. Furthermore studies show (Perkins, 1999) that nicotine dependence in women may relate more to sensory and social cues.

Withdrawal severity was similar in female adolescents, regardless of hormonal contraceptive use. However, craving as a separate item varied according to hormone use, such that those using hormonal contraceptives experienced greater craving than those who were not using hormonal contraceptives. Perhaps hormonal contraceptives effect on craving, not withdrawal, is more pronounced. There is an overlap between premenstrual symptoms and withdrawal symptoms (Allen, Hatsukami, Christianson, & Nelson, 1999) and since hormonal contraceptives can diminish premenstrual symptoms, withdrawal symptoms may be blunted such that a difference between adolescents with and without hormonal contraceptives would not be discernable. Yet craving acts more as an independent item and does not overlap with premenstrual symptoms and therefore might be more prominent.

The observed effects of hormonal birth control on craving may be limited by a variety of factors other than the underlying hormonal mechanisms of birth control use. First, only a small number of females were using hormonal contraceptives while enrolled in the study. Because this was an observational study, females were not randomized into groups of hormonal contraceptive users versus non-users. Given these small numbers we were unable to assess differences between those using combined estrogen/progesterone hormonal contraceptives compared to those using progesterone-only hormonal contraceptives. Second, the hormonal contraceptives that were utilized during the study were comprised of varying doses of different hormones. For the purposes of this study, a female’s use of birth control was classified simply as a “hormonal contraceptive use” or not. Further, some of the combined contraceptives were of varying chemical compositions throughout the menstrual cycle (triphasic oral contraceptives) while others had constant chemical compositions throughout the menstrual cycle (monophasic oral contraceptives). Future studies using a consistent monophasic birth control pill to deliver a constant dose of estrogen and progesterone would provide a stronger model to measure if ovarian hormones have an effect on withdrawal.

This report has some additional limitations. The numbers of females on HC and the variation of the type of HC limited the power of the groups. The retrospective nature limits interpretability of the effect of HC.

This study provides new information on gender differences in withdrawal and craving in adolescents attempting to quit smoking using nicotine replacement. The data suggests that female adolescents experience similar NW as males but have higher levels of craving. The use of HC may also impact the level of craving in females although this needs to be replicated in a larger study controlled for HC use. However it is prudent to address these different symptoms in adolescent males and females to increase smoking cessation outcomes in adolescents

Acknowledgments

This research was supported by NIDA grants R01-DA-014538, P50-DA-09259, and P50-DA-13333. The first author was supported by grants from the Minnesota Medical Foundation and the Minnesota Academy of Family Physicians. Dr. Mooney is supported by a NIDA Career Development award K01-DA-019446.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Allen SS, Bade T, Center B, Finstad D, Hatsukami D. Menstrual phase effects on smoking relapse. Addiction. 2008;103:809–821. [PMC free article] [PubMed]
  • Allen SS, Hatsukami DK, Christanson D, Nelson D. Withdrawal and pre-menstrual symptomatology during the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smoking abstinence. Nicotine & Tobacco Research. 1999;1:129–142. [PubMed]
  • Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clinical Pharmacology & Therapeutics. 2006;79:480–488. [PubMed]
  • Bjornson W, Rand C, Connett JE, Lindgren P, Nides M, Pope F, Buist AS, Hoppe-Ryan C, O’Hara P. Gender differences in smoking cessation after 3 years in the Lung Health Study. American Journal of Public Health. 1995;85:223–230. [PubMed]
  • Carpenter MJ, Saladin ME, Leinbach AS, Larowe SD, Upadhyaya HP. Menstrual phase effects on smoking cessation: a pilot feasibility study. Journal of Women’s Health. 2008;17:293–301. [PubMed]
  • Carpenter MJ, Upadhyaya HY, LaRowe SD, Saladin ME, Brady KT. Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: A review. Nicotine & Tobacco Research. 2006;8:627–638. [PubMed]
  • DiFranza JR, Savageau JA, Fletcher K, O’Loughlin J, Pbert L, Ockene JK, McNeill AD, Hazelton J, Friedman K, Dussault G, Wood C, Wellman RJ. Symptoms of tobacco dependence after brief intermittent use: the Development and Assessment of Nicotine Dependence in Youth-2 study. Archives of Pediatrics & Adolescent Medicine. 2007;161:704–710. [PubMed]
  • Disshon KA, Dluzen DE. Use of in vitro superfusion to access the dynamics of striatal dopamine clearance: influence of estrogen. Brain Research. 1999;842:399–407. [PubMed]
  • Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O’Brien CP, Childress AR. Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. Journal of Women’s Health. 2008;17:287–292. [PMC free article] [PubMed]
  • Gourlay SD, Forbes A, Marriner T, Pethica D, McNeil JJ. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. British Medical Journal. 1994;309:842–846. [PMC free article] [PubMed]
  • Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. Nicotine & Tobacco Research. 2003;5:515–526. [PubMed]
  • Hatsukami DK, Skoog K, Allen S, Bliss R. Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Experimental and Clinical Psychopharmacology. 1995;3:163–173.
  • Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 1991;86:1119–1127. [PubMed]
  • Hogle JM, Curtin JJ. Sex differences in negative affective response during nicotine withdrawal. Psychophysiology. 2006;43:44–56. [PubMed]
  • Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry. 1986;43:289–294. [PubMed]
  • Hughes JR, Hatsukami D. Errors in using tobacco withdrawal scale. Tobacco Control. 1998;7:92–93. [PMC free article] [PubMed]
  • Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Lerman C, Pickworth WB. Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Experimental and Clinical Psychopharmacology. 2007;15:21–36. [PMC free article] [PubMed]
  • Marks JL, Pomerleau CS, Pomerleau OF. Effects of menstrual phase on reactivity to nicotine. Addictive Behavior. 1999;24:127–134. [PubMed]
  • O’Hara P, Portser SA, Anderson BP. The influence of menstrual cycle changes on tobacco withdrawal syndrome in women. Addictive Behavior. 1989;14:595–600. [PubMed]
  • Panday S, Reddy SP, Ruiter RA, Bergstrom E, de Vries H. Nicotine dependence and withdrawal symptoms among occasional smokers. Journal of Adolescent Health. 2007;40:144–150. [PubMed]
  • Perkins KA, Levine M, Marcus M, Shiffman S, D’Amico D, Miller A, Keins A, Ashcom J, Broge M. Tobacco withdrawal in women and menstrual cycle phase. Journal of Consulting & Clinical Psychology. 2000;68:176–180. [PubMed]
  • Perkins KA. Nicotine self-administration. Nicotine & Tobacco Research. 1999;1(Suppl 2):S133–S137. discussion S139–S140. [PubMed]
  • Smith AE, Cavallo DA, Dahl T, Wu R, George TP, Krishnan-Sarin S. Effects of acute tobacco abstinence in adolescent smokers compared with nonsmokers. Journal of Adolescent Health. 2008;43:46–54. [PMC free article] [PubMed]
  • Swan GE, Jack LM, Ward MM. Subgroups of smokers with difference success rates after use of transdermal nicotine. Addiction. 1997;92:207–217. [PubMed]
  • Thompson TL, Moss RL. Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects. Journal of Neurochemistry. 1994;62:1750–1756. [PubMed]